Microchimerism after heart transplantation: prevalence, predisposing factors, natural history, and prognosis by Crespo-Leiro, María Generosa et al.
Transplantation Proceedings. 2002; 34(1): 161-163 
Microchimerism after heart transplantation: prevalence, 
predisposing factors, natural history, and prognosis 
M.G Crespo-Leiro, M Hermida-Prieto, J.A Rodriguez, J Muñiz, S Barral, M.J Paniagua, 
L.F Hermida, A Juffé, A Castro-Beiras 
The success of heart transplantation (HT) is still marred by the need for chronic immunosuppression 
using agents that display not only limited efficacy and specificity but also considerable toxicity.
1
 Overall 
1-year survival is only 81%, and patient half-life (the time at which the survival rate has dropped to 50%) 
is 9.8 years.
2
 The induction of tolerance to transplanted organs, might make transplantation safer as well 
as more successful. 
Certain studies of recipients of solid organs, including liver,
3
 and 
4
 kidney,
5
 lung,
6
 and heart
7
 seem to 
be associated with apparent induction of tolerance and with the persistence of low levels of donor cells of 
bone marrow origin (microchimerism).
8
 Other studies, however, have not found an association between 
microchimerism and tolerance,
9
 and 
10 
and there have also been cases of apparently tolerant recipients 
who do not show detectable microchimerism.
11
 These discrepancies may be explained by differences in 
the prevalence of microchimerism depending on the organ type and the time after transplantation.
12
 and 
13
 
Despite these controversies, some workers have attempt to increase the possibility of tolerance by 
induction enhancing microchimerism via donor bone marrow infusion (DBMI) at the time of 
transplantation.
5
 and 
14
 The work described herein includes studies of the prevalence and natural history 
of microchimerism after HT, as well as predisposing factors to establish the state, and its relevance to the 
outcomes of survival, rejection and steroid requirements. 
Patients and methods 
We determined whether 25 consecutive HT patients exhibited donor microchimerism 3, 6, 12, and 24 
months after HT. Immunosuppression was effected with cyclosporin, mycophenolate mofetil, prednisone, 
and OKT3. The variables examined as possibly predisposing to chimerism were age, sex and weight of 
donor and recipient, OKT3 dose, and allograft ischemic time. Clinical variables examined as possibly 
being affected by microchimerism included the number of rejection episodes, total steroid dose, and 
survival. 
Anticoagulated peripheral blood was obtained from donor and recipient before the transplant 
procedure, and from the recipient 3, 6, 12, and 24 months after HT. Genomic DNA was isolated from 
leukocytes using a Qiagen kit (Qiagen GmbH, Hilden, Germany) and stored at −20°C until use. 
HLA/DRB typing was performed by SSP-PCR (PCR amplification with sequence-specific primers) 
using 24 primer mixes as described.
15
 and 
16
 Before PCR, 5 μL aliquots of primer mixes of appropriate 
concentrations were stored at −20°C in 96-well reaction plates (Applied Biosystems, Foster City, Calif, 
USA). At the time of PCR, 5 μL of a PCR solution was added to each of the primer mixes, giving final 
concentrations as follows: KCl, 50 mmol/L; MgCl2, 1.5 mmol/L; Tris-HCI (pH 8.3), 10 mmol/L; 
glycerol, 5%; dNTPs, 0.2 mmol/L each; Cresol Red, 10 mg/mL; DNA, 100 ng; Taq polymerase (Gibco-
Life Technologies, Gaithersburg, Md, USA), 0.4 U. Amplification was performed in a GeneAmp 9700 
PCR system thermal cycler (Applied Biosystems) as follows: denaturalization at 94°C for 2 minutes, 
followed by 10 cycles of 94°C for 10 seconds and 66°C for 1 minute, followed by 24 cycles of 94°C for 
10 seconds, 61°C for 50 seconds, and 72°C for 30 seconds. The limit of detection of this technique was 
between 1 and 10 donor cells per 100,000 recipient cells, as estimated by application to serial dilutions of 
donor cells within an aliquot of recipient cells bearing a known HLA/DRB haplotype. All PCR products 
were subjected to electrophoresis for 30 minutes at 250 V in 1.5% agarose gels containing ethidium 
bromide, and were visualized using UV illumination. 
  
Results 
During the 24 months following HT, microchimerism was at some time detected in 14 of the 25 
patients (56%). The prevalence increased with time after HT, being 8%, 8%, 32% and 40% at 3, 6, 12, 
and 24 months, respectively (Table 1). With regard to possible predisposing factors, there was no 
relationship between microchimerism and recipient or donor sex or age, recipient weight, allograft 
ischemic time or number of days of OKT3 treatment, but donor weight was on average 11 kg less among 
cases with microchimerism than among those without (P < .01); see Table 2). With regard to clinical 
effects, there was no relationship between microchimerism and number of rejection incidents, total steroid 
dose, or survival (Table 2). There was one death in the group with chimerism (18 months after HT due to 
allograft vasculopathy), and one in the group without chimerism (3 months after HT due to lung cancer). 
Table 1. Course of Microchimerism Status in the 14 Patients Who Exhibited 
Microchimerism at Some Time After Heart Transplant 
Patient Number 3 Months 6 Months 12 Months 24 Months 
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Table 2. Factors Investigated as Potentially Affecting or Being Affected by Microchimerism After Heart Transplant: Values in 
Groups With and Without Detected Microchimerism 
 
Microchimerism (n = 14) No Microchimerism (n = 11) P 
    
Recipient age (y) 61.9 ± 4.2 55.8 ± 8.4 .057 
Donor age (y) 33.7 ± 12.9 37.6 ± 8.1 .386 
Recipient weight (kg) 73.6 ± 13.7 74.8 ± 12.4 .833 
Donor weight (kg) 70.6 ± 6.4 81.9 ± 10.1 .009 
Male recipients (%) 77 90 .412 
Male donors (%) 85 80 .772 
Ischemic time (min) 150.9 147.8 .924 
OKT3 (d) 4.4 ± 1.8 4.5 ± 2.3 .894 
Rejections 1.5 ± 1.3 1.1 ± 1.4 .448 
Total steroid dose (mg) 3404 ± 2497 2300 ± 1806 .281 
Deaths (%) 1 (7.1) 1 (9) NS 
    
 
 
 
Discussion 
In animal models of allotransplant
17 
or xenotransplant
18
 the induction of chimerism appears to prolong 
graft survival. It has been suggested that microchimerism is an important or perhaps essential factor for 
long-term graft acceptance and tolerance by humans.
19
 As a result, DBMI has been performed at the time 
of solid organ transplants to augment chimerism with the aim of enhancing graft acceptance and reducing 
immunosuppression requirement.
5
 The largest DBMI series involving HT patients that we know of was 
reported by Pham et al
14
 (when our study was already under way); among 28 patients who received 
DBMI, the proportion who were free from grade 3A rejection after 6 months was larger than among 24 
controls (64% versus 40%), although after 3 years there were no differences between the two groups in 
either survival or prevalence of coronary artery disease. 
It is known that the HT allograft has fewer passenger leukocytes than in the case of liver or lung 
transplants,
20
 which may make it less effective in inducing chimerism. It has also been suggested that 
treatment with antilymphoid agents might be effective for induction of tolerance.
20
 However, it is not 
known whether treatment with OKT3 in the immediate post-HT period enhances chimerism. In this study, 
we found no relationship between the number of days of OKT3 treatment and chimerism. 
Series in which microchimerism after solid organ transplant did not appear to benefit allograft 
tolerance
9
 and 
10
 have suggested that in those series in which microchimerism was associated with 
improved tolerance the association may have been merely circumstantial.
21
 However, the former series9 
involved just one determination of microchimerism status per patient; since it has been shown that 
microchimerism status changes with time,
12
 a single determination is not enough to allow clinical 
conclusions to be drawn.
13
 
In our study, we detected microchimerism in 56% of our patients at some time during the first 24 
months after HT, but prevalence incresased with time from 8% at 3 months to 40% at 24 months (Table 
1). This increase in prevalence contrasts with the results of Pham et al,
14
 who found that the prevalence of 
chimerism detectable by flow cytometry did not change significantly between 2 and 20 months post-HT 
in the absence of DBMI (40% and 38%, respectively), and that when DBMI was performed prevalence 
fell from 85% at 2 months to 22% at 20 months. 
In this study, most of the variables examined as potentially predisposing factors were not found to be 
related to microchimerism. The only significant relationship observed was with donor weight, which on 
average was 11 kg less among cases with microchimerism than among those without (P < .01; see Table 
1). Although we have no idea of how donor weight might affect microchimerism, this apparent 
relationship certainly seems to deserve further examination in studies of larger series of patients. 
We also failed to detect any clinical consequences of microchimerism, but in this case the possibility 
of detection was severely limited by small sample size, since death rates and rejection rates were low in 
both groups and the variance of total steroid dose was very large (Table 2). 
Conclusions 
Microchimerism can be detected in approximately 50% of HT patients at some time after surgery, the 
prevalence increasing with time. The clinical relevance of microchimerism is not known with any 
certainty, nor are the factors that may favour its appearance, although the intriguing significant 
relationship with donor weight found in this study would seem to deserve further investigation. Until 
studies with larger numbers of patients throw more light on whether microchimerism does really favor 
tolerance, treatments aimed at augmenting the former to enhance the latter appear not to be justified. 
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